… if I’d missed the Psychedelic Science in the 21st Century conference:
1. There’s evidence that MDMA and MDE can help some people with autistic-spectrum disorders.
2. There’s evidence that ultra-low (non-psychoactive) doses of a hallucinogen called DOI can interrupt the inflammatory process implicated in both allergy and auto-immune disorders such as lupus.
3. There’s evidence that barely-psychoactive doses of psilocybin can provide temporary relief from OCD symptoms in some patients.
4. The trials of MDMA in the treatment of refractory post-traumatic stress disorder and of psilocybin in helping people deal with possibly-terminal illness are producing impressive results.
5. Lots and lots and lots of serious science is going on, much of it using cutting-edge brain imaging, and younger scientists are starting to be willing to make career commitments to this long-marginalized research enterprise.
6. Procedures for “guiding” in therapeutic settings are now becoming manualized.
I’m now prepared to bet that one of the classic hallucinogens (psilocybin, LSD, mescaline) or one of the entactogens (MDMA or MDE) will be an FDA-approved medicine before this decade is out. I wouldn’t have made that bet five years ago.